Can a 59-year-old man with hypertension (blood pressure 150/90 mmHg) and normal renal function (serum creatinine 0.59 mg/dL, eGFR 90 mL/min) safely continue valsartan 320 mg and chlorthalidone 25 mg while undergoing chemotherapy?

Can This Patient Continue Valsartan 320 mg and Chlorthalidone 25 mg During Chemotherapy?

Yes, this 59-year-old man can safely continue both valsartan 320 mg and chlorthalidone 25 mg during chemotherapy, with close monitoring of blood pressure, renal function, and electrolytes. His current blood pressure of 150/90 mmHg requires treatment, and his excellent renal function (creatinine 0.59 mg/dL, eGFR 90 mL/min) supports the use of both agents.

Rationale Based on Cardio-Oncology Guidelines

The Canadian Cardiovascular Society guidelines specifically address hypertension management during cancer therapy 1. Treatment for cancer patients can be started with a diuretic, ACE inhibitor, angiotensin receptor blocker (ARB), or calcium channel blocker, with the choice tailored to the individual clinical situation including potential drug-drug interactions 1.

Blood Pressure Target

• Target BP should be <140/90 mmHg (his current 150/90 mmHg is above goal) 1
• Weekly BP monitoring is recommended during the first cycle of chemotherapy, then every 2-3 weeks throughout cancer therapy 1

Specific Medication Considerations

Valsartan (ARB)

Valsartan is appropriate and safe in this patient:

• His normal renal function (eGFR 90 mL/min) is well within the safe range - no dose adjustment needed for eGFR >30 mL/min 2
• The 320 mg dose is within FDA-approved dosing for hypertension 2
• ARBs are explicitly mentioned as acceptable first-line agents in cancer patients 1
• Recent evidence shows valsartan reduces proteinuria and is well-tolerated even in advanced CKD 3, 4

Chlorthalidone

Chlorthalidone 25 mg is appropriate:

• The 25 mg dose is the standard initial dose for hypertension per FDA labeling 5
• His excellent renal function (eGFR 90) supports thiazide use - chlorthalidone is effective even in advanced CKD (eGFR ~23) 6
• Thiazide diuretics are explicitly recommended as acceptable agents in cancer patients 1

Critical Monitoring Requirements

Close attention to volume status and renal function at baseline and throughout therapy is warranted, as this will affect the choice of antihypertensive agent and need for dose adjustments 1:

Weekly During First Chemotherapy Cycle:

• Blood pressure measurements
• Serum potassium (chlorthalidone increases hypokalemia risk 7, 6)
• Serum creatinine/eGFR

Every 2-3 Weeks During Ongoing Chemotherapy:

• Blood pressure
• Electrolytes (potassium, sodium)
• Renal function

Specific Safety Concerns to Monitor:

Hypokalemia: Chlorthalidone carries higher risk than hydrochlorothiazide (8.9% vs 6.9%) 7. Check potassium regularly and consider supplementation if K+ <3.5 mmol/L.

Renal Function: While both agents are safe at his current eGFR, chemotherapy itself may affect kidneys. Hold medications if:

• Serum creatinine increases ≥30% from baseline 8
• eGFR drops below 30 mL/min (would require reassessment) 2

Hyperkalemia: Less common with this combination, but monitor if potassium >5.5 mmol/L 1

Volume Depletion: Cancer patients may experience nausea, vomiting, or diarrhea during chemotherapy. If dehydration occurs, temporary dose reduction or holding diuretic may be needed 2

Drug-Drug Interactions

Be cautious with drugs metabolized by cytochrome P450 system (though valsartan and chlorthalidone have minimal interactions) 1. The specific chemotherapy regimen should be reviewed for:

• NSAIDs (may reduce antihypertensive effect and worsen renal function) 2
• Lithium (if used, requires close monitoring) 2
• Other QT-prolonging agents (many chemotherapy drugs prolong QT) 9, 1

Common Pitfalls to Avoid

1. Don't discontinue effective antihypertensives preemptively - uncontrolled hypertension during chemotherapy increases cardiovascular risk 1

2. Don't ignore volume status - chemotherapy-induced nausea/vomiting may require temporary diuretic adjustment 1

3. Don't forget baseline ECG - many chemotherapy agents prolong QT interval; establish baseline before starting 1

4. Don't overlook potassium supplementation - proactive potassium monitoring and replacement prevents complications 6

Bottom Line

Continue both medications with intensified monitoring. The combination of an ARB and thiazide diuretic is guideline-supported for cancer patients with hypertension 1. His excellent baseline renal function provides a safety buffer, but the monitoring schedule must be strictly followed given the additive risks of chemotherapy, diuretic therapy, and potential volume depletion.